Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients
Launched by TAIPEI MEDICAL UNIVERSITY WANFANG HOSPITAL · Dec 8, 2010
Trial Information
Current as of May 09, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 20 or more than 20 years of age
- • The pathological diagnosis confirmed lung cancer
- • Patients have achieved pleural effusion, or surgical biopsy to obtain tumor tissue specimens
- • The patient had signed inform consent
- Exclusion Criteria:
- • pleural effusion or tumor tissue can not be obtained
- • the patient is not suitable to join the research according to the judgement by the investigator
About Taipei Medical University Wanfang Hospital
Taipei Medical University Wan Fang Hospital is a leading healthcare institution in Taiwan, renowned for its commitment to advancing medical research and improving patient care. As a prominent clinical trial sponsor, the hospital combines cutting-edge medical technology with a multidisciplinary approach to research, facilitating innovative studies that address critical health challenges. With a focus on ethical standards and patient safety, Wan Fang Hospital collaborates with a network of medical professionals and researchers to contribute valuable insights to the global medical community. Its dedication to excellence in clinical trials underscores its role as a pivotal player in the advancement of healthcare practices and therapeutic developments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Patients applied
Trial Officials
Hsin-Gjin Eugene Liu
Principal Investigator
Taipei Medical University WanFang Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials